XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Note 9 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9  - Subsequent Events Lease Cancellation On April 1, 2020, the Company provided notice of cancellation of our lease in the Cambridge Innovation Center in Cambridge, Massachusetts, effective on April 30, 2020.  Share Issuance On April 1, 2020, the Company issued 5,000 shares of stock to a service provider in consideration of services to be provided through June 30, 2020. Option Issuance On April 24, 2020, the Company granted stock options to a new employee to purchase 50,000 shares of common stock. Warrant Issuance On April 24, 2020, the Company issued a warrant to purchase 500,000 shares of common stock at an exercise price of $2.27 per share to a related party in conjunction with past and future services provided to the Company.  Separation Agreement with President & CSO On April 27, 2020, Dr. Julien Pham resigned as the Company's President and Chief Scientific Officer. In connection with Dr. Pham’s resignation, the Company entered into a Separation Agreement with him pursuant to which Dr. Pham will continue to comply with certain restrictive covenants and obligations of confidentiality and in return will be entitled to receive (i) payment of five months of Dr. Pham’s base salary of $375,000, or an aggregate of $156,250, (ii) reimbursement for five months of insurance coverage under the Consolidated Omnibus Budget Reconciliation Act, if incurred, (iii) accelerated vesting of stock options with time-based vesting that would have vested had Dr. Pham remained employed with the Company, with the total number of shares for which such newly vested options are exercisable being 410,117. License Agreement On May 4, 2020, the Company entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on Behalf of the MD Anderson relating to a portfolio of 16 patent applications and related technology for the treatment of cancer using the Company’s lead drug candidate and immunotherapies.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

+ Details

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration